RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
G1 Therapeutics Stock

G1 Therapeutics P/S 2024

G1 Therapeutics P/S

2.23

Ticker

GTHX

ISIN

US3621LQ1099

WKN

A2DR0J

As of Dec 17, 2024, G1 Therapeutics's P/S ratio stood at 2.23, a 40.25% change from the 1.59 P/S ratio recorded in the previous year.

The G1 Therapeutics P/S history

G1 Therapeutics Aktienanalyse

What does G1 Therapeutics do?

G1 Therapeutics Inc is a biopharmaceutical company that was founded in 2008 and is headquartered in Research Triangle Park, North Carolina, USA. The company specializes in the treatment of cancer and is dedicated to improving the quality of life for cancer patients. G1 Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding G1 Therapeutics's P/S Ratio

G1 Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing G1 Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating G1 Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in G1 Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about G1 Therapeutics stock

What is the price-to-earnings ratio of G1 Therapeutics?

The price-earnings ratio of G1 Therapeutics is currently 2.23.

How has the price-earnings ratio of G1 Therapeutics changed compared to last year?

The price-to-earnings ratio of G1 Therapeutics has increased by 40.25% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of G1 Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of G1 Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of G1 Therapeutics affect the company?

An increase in the price-earnings ratio of G1 Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of G1 Therapeutics affect the company?

A decrease in the price-earnings ratio of G1 Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of G1 Therapeutics?

Some factors that influence the price-earnings ratio of G1 Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does G1 Therapeutics pay?

Over the past 12 months, G1 Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, G1 Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of G1 Therapeutics?

The current dividend yield of G1 Therapeutics is .

When does G1 Therapeutics pay dividends?

G1 Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of G1 Therapeutics?

G1 Therapeutics paid dividends every year for the past 0 years.

What is the dividend of G1 Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is G1 Therapeutics located?

G1 Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von G1 Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of G1 Therapeutics from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did G1 Therapeutics pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of G1 Therapeutics in the year 2023?

In the year 2023, G1 Therapeutics distributed 0 USD as dividends.

In which currency does G1 Therapeutics pay out the dividend?

The dividends of G1 Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von G1 Therapeutics

Our stock analysis for G1 Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of G1 Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.